-
-
-
-
-
-
-
Mereo BioPharma Provides Corporate Update
-
-
-
-
-
-
-
Ultragenyx and Mereo advance UX143 osteogenesis imperfecta study to final analysis
-
-
-
-
-
-
-
Mereo BioPharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
-
-
-
-
-
-
-
Mereo BioPharma (MREO) Prices 12.53M Share Offering at $3.99/sh
-
-
-
-
-
-
-
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference
-
-
-
-
-
-
-
Phase 2 Data from “ASTRAEUS” Trial of Mereo BioPharma’s Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease Presented at the 2023 American Thoracic Society International Confere
-
1,199,633 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

